Nocturnal hypoxemia is a frequent yet under-recognized physiologic consequence of chronic obstructive pulmonary disease (COPD). Even in patients who maintain adequate oxygenation during wakefulness, sleep introduces a series of ventilatory and gas exchange challenges that can precipitate clinically meaningful desaturation. These events may occur independently of daytime hypoxemia and are often not captured during routine outpatient assessment. Overnight pulse oximetry (ONO or OPO) offers a practical, scalable method to characterize nocturnal oxygenation patterns in the home environment and has become an increasingly utilized tool at the interface of pulmonology and sleep medicine1.
This review summarizes the physiologic basis of nocturnal hypoxemia in COPD, the technical and clinical utility of OPO, and the evidence supporting its role in contemporary practice. Emphasis is placed on appropriate interpretation and how OPO findings can inform downstream diagnostic and management decisions, particularly in relation to COPD–obstructive sleep apnea (OSA) overlap and oxygen therapy assessment.
PATHOPHYSIOLOGY OF NOCTURNAL HYPOXEMIA IN COPD
Sleep induces predictable changes in respiratory physiology that disproportionately affect patients with COPD2. During non-rapid eye movement (NREM) sleep, minute ventilation declines as metabolic demand and central respiratory drive decrease3. In rapid eye movement (REM) sleep, atonia of accessory respiratory muscles further compromises ventilation, particularly in individuals with hyperinflation and diaphragmatic dysfunction. These changes exacerbate ventilation–perfusion mismatch, already a defining feature of COPD, leading to transient or sustained reductions in arterial oxygen tension.
Nocturnal hypoxemia in COPD may occur in the absence of significant daytime hypoxemia and is not always correlated with forced expiratory volume in one second (FEV₁)4. The presence of comorbid sleep-disordered breathing, particularly OSA, further amplifies nocturnal desaturation through repetitive upper airway obstruction and cyclical hypoxemia. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) highlights the clinical importance of recognizing COPD–OSA overlap, noting its association with increased exacerbations, cardiovascular morbidity, and mortality when untreated5.
CLINICAL CONSEQUENCES OF NOCTURNAL HYPOXEMIA
Intermittent and sustained nocturnal hypoxemia have been linked to multiple downstream pathophysiologic processes. Hypoxic pulmonary vasoconstriction during sleep may contribute to pulmonary hypertension progression, while recurrent oxygen desaturation promotes sympathetic activation, systemic inflammation, and oxidative stress. Observational studies have associated nocturnal hypoxemia with arrhythmias, impaired sleep quality, neurocognitive dysfunction, and reduced health-related quality of life6.
Despite these associations, the causal relationship between nocturnal hypoxemia and long-term outcomes in COPD remains incompletely defined. Importantly, the presence of nocturnal desaturation does not necessarily imply that nocturnal oxygen supplementation will modify disease trajectory, underscoring the need for careful interpretation of physiologic data.
WHAT OVERNIGHT PULSE OXIMETRY MEASURES
Overnight pulse oximetry provides continuous, noninvasive measurement of peripheral oxygen saturation and pulse rate throughout the sleep period1,7. Unlike spot oximetry obtained during clinic visits, OPO captures the temporal dynamics of nocturnal oxygenation, allowing clinicians to quantify desaturation burden and identify recurring patterns.
Commonly reported metrics include mean nocturnal oxygen saturation, minimum saturation, and the cumulative time spent below clinically relevant thresholds, most often expressed as time spent with SpO₂ below 90 percent (T90). Many devices also report the oxygen desaturation index (ODI), reflecting the frequency of transient desaturation events per hour. More recently, composite measures such as desaturation burden, which integrate depth and duration of hypoxemia, have been explored as potentially superior markers of cardiopulmonary risk.
It is essential to recognize that OPO does not measure airflow, respiratory effort, sleep stages, or carbon dioxide levels. As a result, it cannot distinguish between hypoxemia caused by COPD-related gas exchange abnormalities, obstructive respiratory events, hypoventilation, or artifact7,8.
PREVALENCE AND VARIABILITY OF NOCTURNAL DESATURATION IN COPD
Studies have demonstrated that nocturnal oxygen desaturation is common in COPD, including among patients who do not meet criteria for long-term oxygen therapy (LTOT)8. However, prevalence estimates vary widely depending on patient selection and the definition of desaturation employed. Importantly, nocturnal hypoxemia in COPD is subject to significant night-to-night variability.
Several seminal works have demonstrated that a single night of oximetry may not reliably classify patients as nocturnal desaturators or non-desaturators, particularly when desaturation is mild or intermittent9-11. This variability has practical implications for clinical decision-making, suggesting that repeat testing may be warranted when results are borderline or when management decisions carry significant consequences.
EVIDENCE FOR NOCTURNAL OXYGEN THERAPY IN COPD
The distinction between detecting nocturnal hypoxemia and demonstrating benefit from treating it is critical. The INOX trial, a randomized, double-blind, placebo-controlled study, specifically evaluated nocturnal oxygen therapy in COPD patients with isolated nocturnal desaturation who did not qualify for LTOT12. Over a follow-up period of up to three years, nocturnal oxygen therapy did not significantly reduce mortality or delay progression to LTOT compared with sham oxygen.
These findings have influenced guideline recommendations. The American Thoracic Society clinical practice guideline on home oxygen therapy concludes that evidence is insufficient to recommend routine nocturnal oxygen therapy for COPD patients without daytime hypoxemia. This does not negate the clinical relevance of nocturnal hypoxemia itself but rather emphasizes that its management should be individualized and evidence-informed.
ROLE OF OPO IN CONTEMPORARY CLINICAL PRACTICE
Within this evidentiary context, the primary value of OPO lies in its ability to identify nocturnal hypoxemia and guide subsequent evaluation. In patients with COPD who report poor sleep quality, morning headaches, unexplained fatigue, or who exhibit signs of pulmonary hypertension disproportionate to spirometric impairment, OPO can reveal clinically relevant nocturnal desaturation that would otherwise remain undetected.
OPO is also particularly useful for identifying patterns suggestive of COPD-OSA overlap. Recurrent, cyclical desaturations raise suspicion for sleep-disordered breathing and can prompt timely referral for formal sleep testing13,14. GOLD emphasizes the importance of recognizing and treating overlap syndrome, as continuous positive airway pressure therapy in this population has been associated with improved outcomes compared with untreated overlap15.
In patients already receiving supplemental oxygen, OPO can be employed to assess the adequacy of nocturnal oxygenation, recognizing that REM-related hypoxemia may persist despite daytime normoxemia. While evidence guiding nocturnal oxygen titration is limited, OPO provides objective data to support individualized clinical judgment.
INTERPRETATION CONSIDERATIONS AND TECHNICAL LIMITATIONS
Accurate interpretation of OPO requires attention to signal quality and contextual factors. Motion artifact, poor peripheral perfusion. and device-specific averaging algorithms are among some factors that can influence saturation readings. There is growing recognition of variability in pulse oximeter performance across skin pigmentation and clinical conditions, reinforcing the importance of cautious interpretation and correlation with clinical findings.
Because OPO does not assess ventilation or carbon dioxide retention, it is insufficient for evaluating nocturnal hypoventilation, which may be particularly relevant in patients with advanced COPD, obesity, neuromuscular weakness, or opioid use. In such cases, polysomnography with capnography or transcutaneous CO₂ monitoring may be required.
CONCLUSION
Overnight pulse oximetry occupies an important niche in the evaluation of COPD patients at risk for nocturnal hypoxemia. While it does not replace comprehensive sleep testing or arterial blood gas assessment, it provides a low-burden, high-yield method to examine nocturnal oxygenation in the home setting. Its greatest clinical value may lie in identifying patients who warrant further diagnostic evaluation, particularly for COPD-OSA overlap, and in contextualizing symptoms that are otherwise unexplained by daytime measures.
As awareness of nocturnal hypoxemia and overlap syndromes increases, OPO can serve as an effective gateway tool that enhances interdisciplinary collaboration between pulmonology and sleep medicine. When interpreted within the bounds of current evidence and guideline recommendations, OPO contributes meaningfully to patient-centered, physiology-driven care in COPD.
ORDER OVERNIGHT PULSE OXIMETRY FOR YOUR PATIENTS
To order overnight pulse oximetry for your patients, fill out our order form and fax with the attached RX to 888.492.0010.
LEARN HOW APRIA SUPPORTS COPD PATIENTS
Sources
1. Singh, Shruti et al. “The uses of overnight pulse oximetry.” Lung India : official organ of Indian Chest Society vol. 37,2 (2020): 151-157. doi:10.4103/lungindia.lungindia_302_19
2. McNicholas, Walter T et al. “Sleep disorders in COPD: the forgotten dimension.” European respiratory review : an official journal of the European Respiratory Society vol. 22,129 (2013): 365-75. doi:10.1183/09059180.00003213
3. Ingrassia, T S 3rd et al. “Influence of sleep state on CO2 responsiveness. A study of the unloaded respiratory pump in humans.” The American review of respiratory disease vol. 144,5 (1991): 1125-9. doi:10.1164/ajrccm/144.5.1125
4. Bradley, T D et al. “Daytime hypercapnia in the development of nocturnal hypoxemia in COPD.” Chest vol. 97,2 (1990): 308-12. doi:10.1378/chest.97.2.308
5. Global Initiative for Chronic Obstructive Lung Disease: 2025 Report.
6. Sawatari, Hiroyuki et al. “Association between hypoxemia and quality of life in patients with heart failure with preserved ejection fraction and sleep-disordered breathing.” Sleep and biological rhythms vol. 23,1 85-93. 5 Nov. 2024, doi:10.1007/s41105-024-00554-9
7. Kent, Brian D et al. “Hypoxemia in patients with COPD: cause, effects, and disease progression.” International journal of chronic obstructive pulmonary disease vol. 6 (2011): 199-208. doi:10.2147/COPD.S10611
8. Plywaczewski, R et al. “Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy.” Chest vol. 117,3 (2000): 679-83. doi:10.1378/chest.117.3.679
9. Noone, Amelia N et al. “The Clinical Relevance of Overnight Oximetry in the Diagnosis of Intermittent Desaturations and the Need for Home Oxygen in the Near-Term and Term Infant.” Children (Basel, Switzerland) vol. 12,10 1341. 5 Oct. 2025, doi:10.3390/children12101341
10 Wojtasz, Izabela, Andrzej Tomski, and Radosław Kaźmierski. "Association between nocturnal oxygen desaturation and ischaemic stroke outcomes." Neurologia i Neurochirurgia Polska 56.3 (2022): 267-275.
11. Terrill, Philip I. "A review of approaches for analysing obstructive sleep apnoea‐related patterns in pulse oximetry data." Respirology 25.5 (2020): 475-485.
12. Lacasse, Yves, et al. "Randomized trial of nocturnal oxygen in chronic obstructive pulmonary disease." New England Journal of Medicine 383.12 (2020): 1129-1138.
13. Bellavance, S et al. “Correlations between the pediatric sleep questionnaire and the pediatric overnight pulse oximetry.” International journal of pediatric otorhinolaryngology vol. 190 (2025): 112245. doi:10.1016/j.ijporl.2025.112245
14. Jones, Paul W., et al. "Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations." Respiratory medicine 108.1 (2014): 129-135.
15. McNicholas, Walter T. "Does obstructive sleep apnea lead to progression of chronic obstructive pulmonary disease." Sleep Medicine Clinics 19.2 (2024): 253-260.
.png)
